Document is current
Any future updates will be listed below
-
Authors
Steins, Anne
van Mackelenbergh, Madelaine G
van der Zalm, Amber P
Klaassen, Remy
Serrels, Bryan
Goris, Sandrine G
Kocher, Hemant M
Waasdorp, Cynthia
de Jong, Joan H
Tekin, Cansu
Besselink, Marc G
Busch, Olivier R
van de Vijver, Marc J
Verheij, Joanne
Dijk, Frederike
van Tienhoven, Geertjan
Wilmink, Johanna W
Medema, Jan Paul https://orcid.org/0000-0003-3045-2924
van Laarhoven, Hanneke WM
Bijlsma, Maarten F https://orcid.org/0000-0001-6627-3229
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (UVA 2013‐5932)
KWF Kankerbestrijding (UVA 2012‐5607)
- License Information
-
More Information
Article History
Received: 2 July 2019
Revised: 11 February 2020
Accepted: 18 February 2020
First Online: 16 March 2020
Conflict of interest
: HWML has acted as a consultant for BMS, Eli Lilly and Company, MSD, Nordic Pharma Group/Taiho, and Servier, and has received unrestricted research grants from Amgen, Bayer Schering Pharma AG, BMS, Celgene, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, MSD, Nordic Pharma Group, Philips, and Roche Pharmaceuticals. MFB has received research funding from Celgene and acted as a consultant to Servier. JWW has received research funding from Celgene and Novartis. HMK has received research funding from Celgene. MGHB has received research funding form Ethicon, Medtronic, and Mylan. None of these companies were involved in the design, conduct, or analysis of this study or drafting of the manuscript and decision to publish.
